| Document |
Document Title |
|
WO/2012/110463 |
The invention relates to an active substance, in particular for treating inflammatory disease conditions in the oral cavity, that can be activated by a light source and comprising indocyanine green, wherein a solvent, in particular water...
|
|
WO/2012/104277 |
The present application relates to a method of monitoring the membrane permeabilization of liposome and the incidental release of a compound of interest.
|
|
WO/2012/104275 |
The present application relates to thermosensitive liposomes encapsulating nanoparticles which can be used in the health sector, in particular in human health. The invention also relates to pharmaceutical and diagnostic compositions comp...
|
|
WO/2012/104277 |
The present application relates to a method of monitoring the membrane permeabilization of liposome and the incidental release of a compound of interest.
|
|
WO/2012/104275 |
The present application relates to thermosensitive liposomes encapsulating nanoparticles which can be used in the health sector, in particular in human health. The invention also relates to pharmaceutical and diagnostic compositions comp...
|
|
WO/2012/090018 |
A composition interacts with a biological cell system that includes bioactive molecules with biomolecular surfaces, cellular components and water molecules with a specific density. The composition includes a biologically active component...
|
|
WO/2012/079121 |
The invention provides a process for producing a composition comprising natural alumino-silicate minerals having improved reactivity for use in methods of animal husbandry, veterinary and pharmaceutical treatment, comprising irradiating ...
|
|
WO/2012/081022 |
The present invention concerns a combination therapy comprising a radiosensitizing agent and radiation, and being effective to inhibit proliferation of cancer stem cells. According to one embodiment, the combination comprises a radiosens...
|
|
WO/2012/077043 |
A method of synthesizing branched gold nanoparticles is described, starting from an aqueous solution of gold nanoparticle spherical seeds, which is subjected to a growth treatment with an aqueous solution comprising hydroxylamine or a sa...
|
|
WO/2012/059515 |
A kit for the localized activation of high concentrations of a drug inhibitor of metalloproteinases in a deep anatomical site of interest in a mammal, comprising liposomal means of encapsulation of the drug, a heater operating within a f...
|
|
WO/2012/060707 |
The invention is directed to a method for preparing a microsphere comprising a lanthanide metal phosphate complex, a microsphere, a powder comprising a number of the microspheres, a suspension comprising the microsphere or the powder, th...
|
|
WO/2012/047629 |
A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techn...
|
|
WO/2012/047629 |
A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techn...
|
|
WO/2012/042446 |
The present invention concerns fibres containing a powdered composition that is capable of emitting radiation in the far infrared in turn comprising a mixture of : a) aluminium or alumina, b) titanium metal or titanium dioxide, and/or si...
|
|
WO/2012/035489 |
The invention relates to the use of 20-(4-carboxyphenyl)-2,13-dimethyl-3,12- diethyl-[22] pentaphyrine as antibacterial agent in photodynamic treatment. This expanded porphyrin derivatized in position 4 with a carboxyphenyl group proved ...
|
|
WO/2012/035489 |
The invention relates to the use of 20-(4-carboxyphenyl)-2,13-dimethyl-3,12- diethyl-[22] pentaphyrine as antibacterial agent in photodynamic treatment. This expanded porphyrin derivatized in position 4 with a carboxyphenyl group proved ...
|
|
WO/2012/028874 |
The invention provides new antineoplastic agents comprising mono-nuclear complexes containing a tetrapyrido[3,2-a:2',3'-c:3'',2''-h:2''',3'''-j]phenazine, tpphz, ligand, these complexes have dual functioningimaging/therapeutic properties...
|
|
WO/2012/029771 |
Provided are a tumor proliferation inhibitor and a method for inhibiting tumor proliferation both of which can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. The present invention provides a tu...
|
|
WO/2012/028898 |
A device (1) for delivering a substance inside a medium, comprising first ultrasound means (11) adapted to generate a first beam of a first ultrasound wave inside the medium towards a first direction (D1), the first beam being directed t...
|
|
WO/2012/020001 |
The present invention relates to methods and pharmaceutical compositions for the treatment of an ocular disease in a subject. More particularly, the present invention relates to a method for treating an ocular disease in a subj ect compr...
|
|
WO/2012/017324 |
The present invention relates to combination pharmaceutical composition comprising an activated-potentiated form of an antibody to gamma interferon, and an activated- potentiated form of an antibody to S-100 protein and method of treatin...
|
|
WO/2012/017398 |
The present invention refers to products obtained from a plant belonging to Origanum Majorana species for use in the treatment of decreased female libido. The present invention also refers to mixtures and to pharmaceutical compositions c...
|
|
WO/2012/017322 |
A pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of inhibiting of production or amplifying elimination of P24 protein.
|
|
WO/2012/017327 |
A pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of treating and preventing the diseases caused by HIV or associated with HIV, including AIDS..
|
|
WO/2012/017323 |
A pharmaceutical composition, comprising an activated-potentiated form of an antibody to HIV protein, and method of treating and preventing the diseases caused by HIV or associated with HIV, including AIDS..
|
|
WO/2012/017328 |
A combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preven...
|
|
WO/2012/014163 |
The present invention refers to an antigen specific echographic contrast medium for diagnostic and/or therapeutic use, a process for the preparation thereof and its uses in ultrasound diagnostic imaging and in therapy. In particular, sai...
|
|
WO/2012/013632 |
The present invention relates to the use of potentiated organ preparations comprising galea aponeurotica for the treatment of alopecia, in particular androgenic alopecia.
|
|
WO/2012/014078 |
Method of treating organic disease of the nervous system, psychoorganic syndrome or encephalopathy of various genesis by administration of activated-potentiated form of antibodies to brain - specific protein S -100 and activated-potentia...
|
|
WO/2012/010973 |
The present invention is concerned with a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-p...
|
|
WO/2012/010978 |
The present invention relates to a method of treating Alzheimer's disease by administration of activated-potentiated form of antibodies to brain-specific protein S-100 and activated-potentiated form of antibodies to endothelial NO synthase.
|
|
WO/2012/010970 |
Method of treating attention deficit hyperactivity disorder (ADHD) and attention deficit disorder (ADD) by administration of activated-potentiate form of antibodies to brain - specific protein S-100 and activated-potentiate form of antib...
|
|
WO/2012/010966 |
The present application provides a pharmaceutical composition for administration to a patient suffering from diabetes and other metabolic disorders, the composition comprises a) an activated-potentiated form of an antibody to human insul...
|
|
WO/2012/010974 |
Combination pharmaceutical compositions comprising an activated-potentiated form of an antibody to endothelial NO synthase and activated potentiated form of an antibody to brain - specific protein S-100 and their use for the treatment of...
|
|
WO/2012/010974 |
Combination pharmaceutical compositions comprising an activated-potentiated form of an antibody to endothelial NO synthase and activated potentiated form of an antibody to brain - specific protein S-100 and their use for the treatment of...
|
|
WO/2012/007886 |
Disclosed are carriers for drugs and/or MR imaging agents having a lipid bilayer shell comprising a phospholipid having two terminal alkyl chains, one being a short chain having a chain length of at most seven carbon atoms, the other bei...
|
|
WO/2012/007839 |
The preset invention provides a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to a S-100 protein, b) an activated-potentiated form of an antibody to histamine, and c) an activated-poten...
|
|
WO/2012/007845 |
The preset invention provides a method of increasing the effect of an activated-potentiated form of an antibody to an endogenous biological molecule by combining said endogenous biological molecule with an activated-potentiated form of a...
|
|
WO/2012/007846 |
The present application provides a pharmaceutical composition for administration to a patient suffering from at least one symptom of a cardiovascular condition, the composition comprising a) an activated-potentiated form of an antibody t...
|
|
WO/2012/007847 |
The present disclosure provides pharmaceutical compositions comprising an activated potentiated form of an antibody to human cannabinoid receptor and use in the treatment of obesity and related metabolic disorders. The present disclosure...
|
|
WO/2012/004399 |
This invention relates to dry pharmaceutical compositions comprising an active ingredient which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative of 5-ALA, or a pharmaceutically acceptable salt thereof. The compositions may b...
|
|
WO/2012/000610 |
The aim of the invention is to improve the water solubility of compounds with a specific structural element that comprises an m-hydroxystyryl group. This is achieved in that said compounds are complexed with alkali polystyrene sulfonate....
|
|
WO/2011/161220 |
Provided herein are improved methods of photodynamic treatment and diagnosis of cancer and non-cancerous conditions in the gastrointestinal tract, e.g. in the colon, and in particular hyperosmotic enema preparations for use in such metho...
|
|
WO/2011/156471 |
The present invention relates to compositions and methods for increasing tissue-radiosensitivity through induction of local hyperthermia. In particular, the present invention provides superparamagnetic, paramagnetic, or ferromagnetic rad...
|
|
WO/2011/156471 |
The present invention relates to compositions and methods for increasing tissue-radiosensitivity through induction of local hyperthermia. In particular, the present invention provides superparamagnetic, paramagnetic, or ferromagnetic rad...
|
|
WO/2011/147926 |
The present invention is directed towards magnetically responsive vesicular compositions comprising (a) a vesicular structure having a membrane enclosing a cavity and (b) at least one stabilized magnetic nanoparticle embedded in said mem...
|
|
WO/2011/148203 |
The discloses involve a therapeutic formulation comprising (i) sulpiride (1); (ii) a homeopathic composition consisting of the Krebs cycle involving compounds and herbal extracts; and (iii) one or more excipients which yield in desired f...
|
|
WO/2011/147926 |
The present invention is directed towards magnetically responsive vesicular compositions comprising (a) a vesicular structure having a membrane enclosing a cavity and (b) at least one stabilized magnetic nanoparticle embedded in said mem...
|
|
WO/2011/145964 |
|
|
WO/2011/143609 |
Formulations of highly diluted genetic material are disclosed. The genetic material may be human genetic material that is associated with a health effect in humans. For example, the genetic material may cause, ameliorate, reduce, or othe...
|
